The case of a 62-year old man diagnosed with radiation-induced meningioma (RIM) after treatment for astrocytoma with an unusually short latency period of 7 months is reported. The patient first presented with a 2-month history of memory decline. Magnetic resonance imaging (MRI) showed a tumour in the left parieto-temporal lobe. Gross total resection was performed and the tumour was confirmed to be an astrocytoma. The patient received cranial radiotherapy 2 weeks later, however 7 months after radiation treatment the patient presented with headache and vomiting. MRI showed massive meningeal enhancement in the left frontal lobe, which progressively enlarged. The patient's clinical condition deteriorated and a second craniotomy was performed with complete removal of the secondary tumour, which was shown to be a malignant meningioma. Immunohistochemical staining identified CD133-positive cells in both tumours. A rare fraction of brain tumour stem cells (BTSC) was isolated from the primary astrocytoma using a serum-free culture system, suggesting that BTSC may have been involved in the rapid emergence of RIM after resection and radiation of the primary astrocytoma.
Introduction
In 1948, Cahan and colleagues 1 proposed criteria to identify whether tumours were induced by radiation treatment. Current, modified criteria are as follows: a latent period must have elapsed between treatment *W Hu and F Shen are co-first authors. W Hu, F Shen, G Chen et al. Brain tumour stem cell-mediated radiation-induced meningioma and the appearance of the tumour; there must be documentation of the absence of the secondary tumour before radiation; and the histology of the secondary tumour must be distinct from the primary tumour.
Many studies have reported the induction of gliomas, sarcomas and meningiomas after radiation. 2 -4 Of these, meningioma is the most common radiation-induced central nervous system (CNS) neoplasm. The latency or induction interval following radiation is a crucial criterion for diagnosis of radiationinduced meningioma (RIM). In the majority of reported cases the mean interval was close to 20 years, 5 -8 most patients having been irradiated as teenagers or even as children. 2, 6, 9, 10 The brain tumour stem cell (BTSC) hypothesis has provided insights into the initiation and recurrence of brain tumours, and several independent research groups have reported a rare BTSC population within brain gliomas of different grades from both children and adults. 11 -13 The cell surface protein, CD133, has been suggested by several studies to be a specific identification marker for BTSCs in primary human gliomas 14, 15 as well as in other malignancies of various histogenesis, such as leukaemia, lung cancer and laryngocarcinoma. 16 -19 The patient presented in the current study is a 62-year-old man who was treated by surgery followed by adjuvant radiotherapy for astrocytoma, who then developed a secondary malignant meningioma at a site different to that of the primary astrocytoma after an unusually short latency period of just 7 months. To our knowledge, this is the shortest latency period to have been reported and the present patient is also the oldest to be reported in the literature for RIM.
Case report
A 62-year old man was admitted to the Second Affiliated Hospital of Zhejiang University School of Medicine in June 2006 with a 2-month history of memory decline. He did not have any symptoms of headache, visual field changes, numbness, weakness or personality changes at that time. Magnetic resonance imaging (MRI) showed a tumour in the left parieto-temporal lobe, close to the left cerebral ventricle ( Figs 1A1 and 1A2) . The patient underwent a left parietotemporal craniotomy and gross total resection of the tumour was achieved. The tumour sample was classified according to World Health Organization guidelines 20 as a grade IV astrocytoma ( Fig. 1A3) .
A post-operative MRI scan was performed 10 days after surgery and showed no sign of residual tumour or recurrence at a different site. The patient received cranial radiation therapy 2 weeks after surgery. Whole-brain radiation (36 Gy in 18 fractions) was given using parallel opposed lateral portals, with a final boost of 20 Gy in 10 fractions to the tumour site. Computed tomography (CT) and MRI scans were performed every 2 months after radiotherapy; no new lesions were seen during this time (Fig. 1B) .
The patient was readmitted to the Second Affiliated Hospital of Zhejiang University School of Medicine in February 2007 with headache, vomiting, and urinary and faecal incontinence. Post-contrast MRI of his brain showed massive meningeal enhancement in the left frontal lobe. An initial diagnosis of a multifocal recurrence of the astrocytoma in other brain regions was made, and treatment with the adjuvant anticancer drug, elemene, was given. In April 2007, the patient began to manifest symptoms of intracranial hypertension, including severe headache and vomiting, accompanied by a deterioration in his level of consciousness. An MRI scan showed that the neoplasm in the left frontal lobe had enlarged, with a W Hu, F Shen, G Chen et al. Brain tumour stem cell-mediated radiation-induced meningioma marked shift of the midline structure ( Fig.  1C1 ). A left frontal craniotomy was immediately performed and the tumour was completely removed. A diagnosis of malignant meningioma was made following pathological and immunohistochemical analyses of the removed tumour, and the patient was treated with traditional Chinese medicines (Mongolian Milkvetch Root and Chinese Angelica) and other routine symptomatic therapies (mannitol for dehydration and nutritional support) after the second surgical resection. He died 6 months later from multiple organ failure.
Overall, the removed tumour was firm, vascular and well-defined, measuring 5 × 4 × 2 cm 3 . Pathological examination showed that many of the nuclei had prominent nucleoli and mitotic figures (Fig. 1C2 ). Immunohistochemical analyses showed that the tumour was positive for epithelial membrane antigen, chromogranin A, the proliferation antigen Ki-67, vimentin and S-100 protein, and negative for glial fibrillary acidic protein, cytokeratin, synaptophysin and CD34.
Samples from both tumours were analysed for CD133 + cells using immunohistochemical staining and these were found in both tumours at a frequency of <8%; the CD133 + rate was higher in the primary astrocytoma ( Fig. 2A ) than the secondary meningioma (Fig. 2B) . The tumour samples were then cultured in serum-free medium 13 (containing Dulbecco's modified Eagle's medium/F12 supplemented with B27, epidermal growth factor and basic fibroblast growth factor), and a rare fraction of tumour sphere-forming cells was isolated from the primary astrocytoma (Fig. 2C) . These cells were not only able to self-renew, proliferate and differentiate into multilinkage progenies after differentiation induction with serum-containing medium in vitro ( Fig. 2D and 2E ), but were also able to initiate tumours in vivo, even after serial transplantations (Fig. 2F) . These results supported the existence of BTSC in this primary astrocytoma, however, no such tumour sphere-forming cells were identified from the secondary meningioma.
Discussion
Although both gliomas and meningiomas are very common intracranial CNS tumours, their association in the same patient is rare.
Ionizing radiation, at both high and low doses, are the main currently recognized risk factors for the development of meningioma. 3, 21, 22 As increasing numbers of CNS malignancies are treated with radiotherapy, the possible associations of this therapy with secondary intracranial meningiomas or gliomas are of growing medical concern. The suggested underlying mechanism is that the greater chromosomal injury invoked by a higher radiation dosage might elicit more rapid loss of cellular control mechanisms and earlier expression of the neoplastic phenotype. 23, 24 A review of the literature showed that most reported RIM have the following characteristics. First, they usually have a long latency period after radiation: although a wide range in the latency period has been reported following high-dose radiation (12 Brain tumour stem cell-mediated radiation-induced meningioma months to 63 years), the mean latency period is 18.7 ± 10.2 years. 2, 3, 6, 7, 25, 26 Secondly, most patients were juveniles: of the patients whose ages were reported, all were in the paediatric age group (the majority < 5 years old at the time of cranial radiation following brain tumour diagnosis) except for one young adult patient. This may be because more chromosomal injury is caused by radiation in the developing nervous tissue of young children 7 and the meninges of children are extremely sensitive and, thus, more vulnerable to radiation. 27 Thirdly, the relationship between the dose of radiation and the latency period is still uncertain: some authors have demonstrated a proportional relationship between a high dose of irradiation (> 20 Gy), particularly in children, and the risk of induced meningiomas with a shorter latency period. 2, 5, 8, 28 however others have not shown a significant correlation between latency period and radiation dose. 7 The case presented here fulfils the criteria for RIM as proposed by Cahan and colleagues. 1 To our knowledge, not only is the unusually short latency period of just 7 months the shortest ever reported but also, at 62 years, this patient is the oldest among the cases in the literature. These peculiar aspects led to the consideration of whether other pathogenic factors might be involved in the case presented here.
Since the initial identification of BTSC from human primary brain tumours, many studies in recent years have implicated this rare cell fraction within the tumour bulk as the origin of tumour initiation and recurrence, indicating a significant clinical value of targeted eradication of BTSC. 11, 29, 30 Magnetic resonance labelling using a CD133 marker that specifically identified BTSC, has suggested that only CD133 + cells from human brain tumours exhibit stem cell properties in vitro and are capable of tumour initiation in vivo. 14, 15 CD133 also has been suggested to be specific for the identification of BTSC from other types of malignancies, including leukaemia, laryngocarcinoma, liver cancer, breast cancer, colon cancer and prostate cancer. 31 -33 This CD133-dependent BTSC identification method is further supported by reports that CD133 + glioblastoma cells are more resistant to ionizing radiation and chemotherapy, because they are more efficient at inducing the repair of damaged DNA and have higher expression of drugresistant proteins and DNA repair proteins than the bulk of tumour cells. 34, 35 The major interests of our research group lie in the identification of BTSC in human primary brain tumours and their matched established cancer cell lines, and in the elucidation of the biological characteristics of BTSC. Intrigued by this rare case of an association between glioma and meningioma and since BTSC may be at the root of brain tumours, the tumour samples were analysed for CD133 + BTSC. The existence of CD133 + cells was found in both tumour samples and the presence of BTSC in the primary astrocytoma was confirmed on serum-free culture. No tumour sphere-forming cells were identified from the secondary meningioma, which may be partially because the serumfree medium was adapted from the neurosphere culture system and was not favourable for the growth of meningioma cells, which are different from astrocytoma cells in terms of their histogenesis.
Although there is currently still no evidence supporting the existence of BTSC in meningiomas, the present case led us to the hypothesis that adjuvant radiotherapy given after resection of the primary astrocytoma may have induced and stimulated the transformation of normal stem cells and/or progenitor cells into CD133 + meningioma BTSC, which then gave rise to fast-growing W Hu, F Shen, G Chen et al. Brain tumour stem cell-mediated radiation-induced meningioma malignant meningioma. Further studies are, however, needed to test this hypothesis and to elucidate the basic underlying mechanisms.
